Press Enter to search · Esc to close
GLP-1s deliver durable fat loss and metabolic wins — but a maturing evidence base is also flagging ocular signals and structural changes worth knowing before you pin or pass.
A new randomized trial suggests a year of structured exercise after weight loss boosts the body's own appetite-quieting GLP-1 — something the injectable drugs don't appear to do. Here's what that means for anyone serious about keeping the weight off.
A new flow-NMR study cracks open how a marketed GLP-1 drug quietly rearranges itself in solution — and why that matters for the next generation of injectables busy men will actually use.
A new meta-analysis pooling seven direct comparisons gives us the cleanest apples-to-apples read yet on how the two big incretin drugs stack up for weight loss.
A retrospective hip-replacement study suggests non-diabetic GLP-1 users may not face the malnutrition penalty surgeons feared — but the questions are bigger than one paper.
A new pooled analysis of randomized trials isolates the non-diabetic obesity population — the use case driving most consumer demand — and quantifies what the dual GIP/GLP-1 agonist actually does, and what it costs.